Compare Eli Lilly And Co (LLY) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.11 (market cap $46.41B). The key difference: Eli Lilly And Co is far larger — about 22.4× Vivmark Residential Common Shares of Beneficial Interest's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays the higher dividend (4.68%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vivmark Residential Common Shares of Beneficial Interest for 1 Days on average.
| LLY | VMRK | |
|---|---|---|
Market Cap | $1.04T | $46.41B |
Volume | 3,064,878 | 6,584,008 |
Sector | Health | Real Estate |
52-Week High | $1.28K | $70.15 |
52-Week Low | $799.57 | $57.98 |
Typical Hold Time | 93 Days | 1 Days |
Enterprise Value | $1.09T | $55.52B |
Dividend Yield | 0.59% | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
